Dimensional Fund Advisors LP Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Dimensional Fund Advisors LP lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 587,025 shares of the biopharmaceutical company's stock after purchasing an additional 16,961 shares during the quarter. Dimensional Fund Advisors LP owned 0.53% of Regeneron Pharmaceuticals worth $418,113,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of REGN. Pamalican Asset Management Ltd purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $4,915,000. Intact Investment Management Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $356,000. Rhenman & Partners Asset Management AB boosted its stake in shares of Regeneron Pharmaceuticals by 11.4% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock worth $30,956,000 after buying an additional 4,457 shares during the last quarter. Principal Financial Group Inc. increased its position in Regeneron Pharmaceuticals by 1.7% during the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock valued at $181,961,000 after acquiring an additional 2,828 shares during the last quarter. Finally, Fagan Associates Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 42.2% in the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock worth $9,205,000 after purchasing an additional 3,832 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on REGN. Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday. JPMorgan Chase & Co. decreased their price objective on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating on the stock in a research note on Monday, March 31st. Piper Sandler decreased their target price on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research note on Monday, January 27th. Bank of America reduced their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research note on Thursday, April 17th. Finally, UBS Group downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $949.60.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded up $2.36 on Wednesday, hitting $587.85. 791,840 shares of the company were exchanged, compared to its average volume of 718,401. The stock's 50 day moving average price is $642.12 and its 200 day moving average price is $732.33. Regeneron Pharmaceuticals, Inc. has a 1-year low of $525.99 and a 1-year high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $64.27 billion, a P/E ratio of 15.36, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company's revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $11.86 earnings per share. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.60%. Regeneron Pharmaceuticals's payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.